Radiation-induced lung injury

Samir Ataya, Jean Elwing, Paul Williams Biddinger, Ralph J. Panos

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Normal lung parenchyma is often unavoidably exposed to radiation during thoracic radiotherapy for bronchogenic and systemic neoplasms. Because the lung is extremely radiosensitive, radiation-induced lung injury occurs commonly. The cellular processes of radiation-induced injury begin within hours after irradiation, but the clinical and radiographic features may not be manifest for weeks to months after exposure. Radiation causes genetic and macromolecular cell injury through direct effects on DNA as well as indirect effects through lipid peroxidation and initiation of apoptotic pathways and inflammatory cascades. Often, the inflammation resolves with minimal parenchymal changes; however, the inflammatory process may progress to parenchymal fibrosis. The risk of radiation lung injury appears to be best predicted by the dose-volume histogram that is calculated from the total radiation dose delivered to a percentage of lung parenchyma. The clinical manifestations of radiation pneumonitis are generally not specific and must be distinguished from respiratory infections. Many patients present with a dry, hacking, usually nonproductive cough and dyspnea. The chest computed tomography scan is more sensitive than the chest radiograph in detecting radiation pneumonitis and usually demonstrates alveolar and interstitial opacifications in the radiation port. Steroids are frequently used to treat radiation pneumonitis. Although minimizing the amount of radiation and shielding are the principal methods to prevent radiation lung injury, amifostine has been demonstrated to reduce the incidence and severity of radiation pneumonitis. Inhaled corticosteroids and keratinocyte growth factor hold promise as future therapeutic agents for the prevention and treatment of radiation lung injury.

Original languageEnglish (US)
Pages (from-to)232-242
Number of pages11
JournalClinical Pulmonary Medicine
Volume13
Issue number4
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Radiation Pneumonitis
Lung Injury
Radiation Injuries
Radiation
Thorax
Lung
Radiation Genetics
Amifostine
Fibroblast Growth Factor 7
Cough
Respiratory Tract Infections
Dyspnea
Lipid Peroxidation
Adrenal Cortex Hormones
Fibrosis
Radiotherapy
Steroids
Tomography
Inflammation
DNA

Keywords

  • Lung injury
  • Radiation
  • Radiation pneumonitis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Radiation-induced lung injury. / Ataya, Samir; Elwing, Jean; Biddinger, Paul Williams; Panos, Ralph J.

In: Clinical Pulmonary Medicine, Vol. 13, No. 4, 01.07.2006, p. 232-242.

Research output: Contribution to journalReview article

Ataya, Samir ; Elwing, Jean ; Biddinger, Paul Williams ; Panos, Ralph J. / Radiation-induced lung injury. In: Clinical Pulmonary Medicine. 2006 ; Vol. 13, No. 4. pp. 232-242.
@article{fe8861c515db47789cb4afdcfaac2a9c,
title = "Radiation-induced lung injury",
abstract = "Normal lung parenchyma is often unavoidably exposed to radiation during thoracic radiotherapy for bronchogenic and systemic neoplasms. Because the lung is extremely radiosensitive, radiation-induced lung injury occurs commonly. The cellular processes of radiation-induced injury begin within hours after irradiation, but the clinical and radiographic features may not be manifest for weeks to months after exposure. Radiation causes genetic and macromolecular cell injury through direct effects on DNA as well as indirect effects through lipid peroxidation and initiation of apoptotic pathways and inflammatory cascades. Often, the inflammation resolves with minimal parenchymal changes; however, the inflammatory process may progress to parenchymal fibrosis. The risk of radiation lung injury appears to be best predicted by the dose-volume histogram that is calculated from the total radiation dose delivered to a percentage of lung parenchyma. The clinical manifestations of radiation pneumonitis are generally not specific and must be distinguished from respiratory infections. Many patients present with a dry, hacking, usually nonproductive cough and dyspnea. The chest computed tomography scan is more sensitive than the chest radiograph in detecting radiation pneumonitis and usually demonstrates alveolar and interstitial opacifications in the radiation port. Steroids are frequently used to treat radiation pneumonitis. Although minimizing the amount of radiation and shielding are the principal methods to prevent radiation lung injury, amifostine has been demonstrated to reduce the incidence and severity of radiation pneumonitis. Inhaled corticosteroids and keratinocyte growth factor hold promise as future therapeutic agents for the prevention and treatment of radiation lung injury.",
keywords = "Lung injury, Radiation, Radiation pneumonitis",
author = "Samir Ataya and Jean Elwing and Biddinger, {Paul Williams} and Panos, {Ralph J.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1097/01.cpm.0000227598.88431.04",
language = "English (US)",
volume = "13",
pages = "232--242",
journal = "Clinical Pulmonary Medicine",
issn = "1068-0640",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Radiation-induced lung injury

AU - Ataya, Samir

AU - Elwing, Jean

AU - Biddinger, Paul Williams

AU - Panos, Ralph J.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Normal lung parenchyma is often unavoidably exposed to radiation during thoracic radiotherapy for bronchogenic and systemic neoplasms. Because the lung is extremely radiosensitive, radiation-induced lung injury occurs commonly. The cellular processes of radiation-induced injury begin within hours after irradiation, but the clinical and radiographic features may not be manifest for weeks to months after exposure. Radiation causes genetic and macromolecular cell injury through direct effects on DNA as well as indirect effects through lipid peroxidation and initiation of apoptotic pathways and inflammatory cascades. Often, the inflammation resolves with minimal parenchymal changes; however, the inflammatory process may progress to parenchymal fibrosis. The risk of radiation lung injury appears to be best predicted by the dose-volume histogram that is calculated from the total radiation dose delivered to a percentage of lung parenchyma. The clinical manifestations of radiation pneumonitis are generally not specific and must be distinguished from respiratory infections. Many patients present with a dry, hacking, usually nonproductive cough and dyspnea. The chest computed tomography scan is more sensitive than the chest radiograph in detecting radiation pneumonitis and usually demonstrates alveolar and interstitial opacifications in the radiation port. Steroids are frequently used to treat radiation pneumonitis. Although minimizing the amount of radiation and shielding are the principal methods to prevent radiation lung injury, amifostine has been demonstrated to reduce the incidence and severity of radiation pneumonitis. Inhaled corticosteroids and keratinocyte growth factor hold promise as future therapeutic agents for the prevention and treatment of radiation lung injury.

AB - Normal lung parenchyma is often unavoidably exposed to radiation during thoracic radiotherapy for bronchogenic and systemic neoplasms. Because the lung is extremely radiosensitive, radiation-induced lung injury occurs commonly. The cellular processes of radiation-induced injury begin within hours after irradiation, but the clinical and radiographic features may not be manifest for weeks to months after exposure. Radiation causes genetic and macromolecular cell injury through direct effects on DNA as well as indirect effects through lipid peroxidation and initiation of apoptotic pathways and inflammatory cascades. Often, the inflammation resolves with minimal parenchymal changes; however, the inflammatory process may progress to parenchymal fibrosis. The risk of radiation lung injury appears to be best predicted by the dose-volume histogram that is calculated from the total radiation dose delivered to a percentage of lung parenchyma. The clinical manifestations of radiation pneumonitis are generally not specific and must be distinguished from respiratory infections. Many patients present with a dry, hacking, usually nonproductive cough and dyspnea. The chest computed tomography scan is more sensitive than the chest radiograph in detecting radiation pneumonitis and usually demonstrates alveolar and interstitial opacifications in the radiation port. Steroids are frequently used to treat radiation pneumonitis. Although minimizing the amount of radiation and shielding are the principal methods to prevent radiation lung injury, amifostine has been demonstrated to reduce the incidence and severity of radiation pneumonitis. Inhaled corticosteroids and keratinocyte growth factor hold promise as future therapeutic agents for the prevention and treatment of radiation lung injury.

KW - Lung injury

KW - Radiation

KW - Radiation pneumonitis

UR - http://www.scopus.com/inward/record.url?scp=33745926835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745926835&partnerID=8YFLogxK

U2 - 10.1097/01.cpm.0000227598.88431.04

DO - 10.1097/01.cpm.0000227598.88431.04

M3 - Review article

VL - 13

SP - 232

EP - 242

JO - Clinical Pulmonary Medicine

JF - Clinical Pulmonary Medicine

SN - 1068-0640

IS - 4

ER -